FLGT - CIK 0001674930
The table below shows Fulgent Genetics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$101.64M | $21.06M | $27.00M | $253.52M | $538.58M | $140.63M |
| Capital expenditure | $22.57M | $40.31M | $22.21M | $18.77M | $23.81M | $35.13M |
| Investing cash flow | $111.37M | -$58.35M | $38.90M | -$261.31M | -$546.55M | -$326.44M |
| Dividends paid | - | - | - | - | - | - |
Fulgent Genetics, Inc. reported operating cash flow of -$101.64M for fiscal year 2025. That is down 582.6% from $21.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $4.41M (FY 2016) to -$101.64M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $10.88M | $225.00K | $25.06M | $74.34M | - | $62.00K |
| Financing cash flow | -$14.79M | -$4.85M | -$47.78M | -$77.14M | $85.41M | $261.25M |